CIK 0001477845 · Non-accelerated filer<br>Smaller reporting company
Annovis Bio, Inc.
Sign in to watch- Ticker
- ANVS
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 262540421
- Phone
- 484-875-3192
- Business address
- 101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA, 19355
- Former names
- QR Pharma, Inc.
- Open-market buys, last 90 days
- $5,000,000
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$5,000,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-04-07 | White Mark K. Director | Grant or award | +3,000 | $12.61 | $38K | 59,177 |
| 2023-04-07 | Bruck Claudine Director | Grant or award | +500 | $12.61 | $6K | 6,567 |
| 2023-04-07 | Hagopian Henry III Chief Financial Officer | Grant or award | +1,000 | $12.61 | $13K | 1,000 |
| 2023-04-07 | Hoffman Michael B Director | Grant or award | +59,477 | $12.61 | $750K | 59,477 |
| 2023-04-07 | McCarthy Reid Director | Grant or award | +476 | $12.61 | $6K | 7,305 |
| 2023-04-07 | Maccecchini Maria-Luisa President and CEO | Grant or award | +20,000 | $12.61 | $252K | 1,060,489 |
| 2023-02-06 | Maccecchini Maria-Luisa President and CEO | Option exercise | +52,755 | $0.14 | $7K | 1,040,489 |
| 2023-02-06 | Maccecchini Maria-Luisa President and CEO | Option exercise · Stock Option (right to buy) | −52,755 | 0 | ||
| 2023-01-18 | Maccecchini Maria-Luisa President and CEO | Grant or award · Stock Option (right to buy) | +21,312 | 21,312 | ||
| 2023-01-18 | Hagopian Henry III Chief Financial Officer | Grant or award · Stock Option (right to buy) | +7,672 | 7,672 | ||
| 2023-01-18 | White Mark K. Director | Grant or award · Stock Option (right to buy) | +5,967 | 5,967 | ||
| 2023-01-18 | McCarthy Reid Director | Grant or award · Stock Option (right to buy) | +5,967 | 5,967 | ||
| 2023-01-18 | Hoffman Michael B Director | Grant or award · Stock Option (right to buy) | +6,820 | 6,820 | ||
| 2023-01-18 | Bruck Claudine Director | Grant or award · Stock Option (right to buy) | +5,967 | 5,967 | ||
| 2022-08-29 | Hagopian Henry III Chief Financial Officer | Grant or award · Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2022-01-14 | Maccecchini Maria-Luisa President and CEO | Option exercise | +32,959 | $0.14 | $5K | 987,734 |
| 2022-01-14 | Maccecchini Maria-Luisa President and CEO | Option exercise · Stock Option (right to buy) | −32,959 | 52,755 | ||
| 2022-01-04 | Hoffman Michael B Director | Option exercise | +30,000 | $4.39 | $132K | 1,415,889 |
| 2022-01-04 | Hoffman Michael B Director | Shares withheld for taxes | −6,658 | $19.78 | $132K | 1,409,231 |
| 2022-01-04 | Hoffman Michael B Director | Option exercise | +7,142 | $0.25 | $2K | 1,416,373 |
Page 4 of 8 · 142 trades